Medindia
Medindia LOGIN REGISTER
Advertisement

Gerresheimer Discontinues Marginal Operations

Thursday, June 19, 2008 General News
Advertisement
DUSSELDORF, Germany, June 18

- Sale of Consumer Healthcare Business

- Concentration on Core Business of Pharmaceutics and Life Science
Advertisement

Gerresheimer AG, the leading manufacturer of glass and plastic productsfor the pharma & life science industry, is selling its consumer healthcarebusiness. As previously announced, the Dusseldorf company is therebydiscontinuing operations which are not part of the core business ofpharmaceutics and life science.
Advertisement

"The consumer healthcare business did not fit in with our strategy offocussing on the fields of pharmaceutics and life science. In addition,because of the lack of synergies with the core business, our returnrequirements for the consumer healthcare business were not fulfilled," saysGerresheimer CEO Dr. Axel Herberg.

The consumer healthcare business, which comprises the production oftoothbrushes and other interdental articles and most recently achieved annualsales of EUR24m, was part of the Wilden Group, which was acquired in January2007. The purchaser is the Krallmann Group. Through the acquisition,Krallmann intends to expand its own plastic processing division and tocontinue the business under the traditional "Interbros" trademark. Thetransaction takes place with effect on 1 June 2008. The contractual partieshave agreed to keep further details confidential.

Early this year, Gerresheimer already discontinued the marginal businessof aluminium packaging with sales of EUR3.3m.

About Gerresheimer

Gerresheimer employs more than 10,800 people in 41 locations in Europe,America and Asia. In the financial year 2007, worldwide sales totalledEUR957.7m. The product portfolio ranges from pharma-ceutical vials made ofglass and plastic through to complex drug-delivery systems for the pharma &life science industry. These include sterile syringes, inhalers and othersystem-based approaches for safe dosage and application of medications. TheGroup enjoys a leading position in markets which are characterised by hightechnical and regulatory barriers.Contact Press Contact Investor Relations Burkhard Lingenberg Anke Linnartz Director Corporate PR & Marketing Director Corporate Investor Relations Telephone +49-211-6181-250 Telephone +49-211-6181-314 Telefax +49-211-6181-241 Telefax +49-211-6181-121 E-mail E-mail [email protected] [email protected]

SOURCE Gerresheimer AG
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close